证券日报网讯 8月13日晚间，海创药业发布公告称，公司第二届监事会第十次会议审议通过了《关于公 司及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - Zhengfan Technology plans to acquire 62.23% equity of Hanjing Semiconductor for a total price of 1.12 billion yuan [1] - Yongji Co. is planning to acquire control of Nanjing Tena Fei Electronic Technology Co. through a combination of issuing shares and cash, with stock suspension expected to last no more than 10 trading days [2] - Aiwai Electronics reported a 71.09% year-on-year increase in net profit attributable to shareholders in the first half of 2025, despite a 13.4% decline in revenue [3] Group 2 - Huabei Pharmaceutical's net profit attributable to shareholders increased by 71.56% year-on-year in the first half of 2025, with a slight revenue growth of 0.84% [4] - Haichuang Pharmaceutical reported a revenue increase of 11,899.08% year-on-year, but incurred a net loss of 61.85 million yuan in the first half of 2025 [5] - Baiwei Storage announced that the National Integrated Circuit Fund II plans to reduce its stake by no more than 2% through block trading [6] Group 3 - Anlu Technology announced that several entities, including the National Integrated Circuit Fund, plan to collectively reduce their stake by no more than 3.25% [7] - Laimu Co.'s controlling shareholder plans to reduce its stake by no more than 3% within three months [8] - Changcheng Military Industry reported significant stock price fluctuations and may apply for a trading suspension if prices continue to rise [9] Group 4 - Beiwai Technology confirmed that its controlling shareholder has not engaged in any stock trading activities during a period of significant price fluctuations [10] - Liangpinpuzi's controlling shareholder is involved in a lawsuit with a disputed amount of 1.023 billion yuan, which may create uncertainties regarding control transfer [11]

Mergers and Acquisitions - Zhengfan Technology plans to acquire 62.23% stake in Hanjing Semiconductor for a total price of 1.12 billion yuan [1] - Yongji Co. is planning to acquire control of Nanjing Tenafly Electronics through a combination of issuing shares and cash, with stock suspension expected to last no more than 10 trading days [2] Performance Disclosure - Aiwei Electronics reported a 71.09% year-on-year increase in net profit attributable to shareholders, with total revenue of 1.37 billion yuan, down 13.4% year-on-year [3] - Huabei Pharmaceutical's net profit attributable to shareholders increased by 71.56% year-on-year, with total revenue of 5.275 billion yuan, up 0.84% year-on-year [4] - Haichuang Pharmaceutical reported a net loss of 61.85 million yuan, despite a significant revenue increase of 11,899.08% to 13.1672 million yuan [5] Shareholding Changes - Baiwei Storage announced that the National Integrated Circuit Industry Investment Fund Phase II plans to reduce its stake by no more than 2%, equating to a maximum of 9.2253 million shares [6] - Anlu Technology disclosed that several entities, including the National Integrated Circuit Industry Investment Fund, plan to collectively reduce their stake by no more than 3.25% [7] - Laimu Co.'s controlling shareholder plans to reduce its stake by no more than 3%, equating to a maximum of 12.8 million shares [8] Legal Matters - Good Products Co.'s controlling shareholder is involved in a lawsuit concerning a stake dispute, with the amount in question reaching 1.023 billion yuan, although it is stated that this will not significantly impact the company's operations or current profits [12]

海创药业2025半年报 ...

Core Viewpoint - The report highlights Haichuang Pharmaceutical's focus on innovative drug development, particularly in the areas of cancer and metabolic diseases, utilizing advanced technologies such as PROTAC and deuterated drugs to address unmet clinical needs [5][9]. Financial Performance - The company reported a revenue of 13.17 million yuan for the first half of 2025, a significant increase of 11,899.08% compared to the same period last year [4]. - The total profit for the period was a loss of 61.85 million yuan, which is an improvement from a loss of 100.40 million yuan in the previous year [4]. - The net profit attributable to shareholders was also a loss of 61.85 million yuan, showing a reduction in losses by 33.63% compared to the previous year [4]. Product Development - The company’s first core product, deuterated enzalutamide soft capsules (HC-1119), received approval from the NMPA and generated sales revenue of 13.07 million yuan [4][8]. - HC-1119 has shown significant clinical benefits, including a 42% reduction in the risk of disease progression or death in patients with metastatic castration-resistant prostate cancer (mCRPC) [8][9]. - The company has a robust pipeline of drugs in various stages of development, including HP518 and HP568, targeting different cancer types and mechanisms [6][10]. Market Strategy - The company is implementing a comprehensive commercialization strategy that includes academic promotion and building a competitive marketing team to enhance brand awareness and market access [9]. - The product HC-1119 has been launched in major cities, marking its entry into the clinical application phase and providing new treatment options for prostate cancer patients [9][10]. Research and Development Focus - Haichuang Pharmaceutical emphasizes innovation in drug development, particularly in addressing the challenges of drug resistance in prostate cancer treatment through its PROTAC technology [10]. - The company aims to leverage its advanced research platforms to enhance its global competitiveness in the pharmaceutical market [5][9].

海创药业股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到上海证券交易所：http://www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本报告 第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 A股 上海证券交易所科 海创药业 688302 无 创板 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书（信息披露境内代 证券事务代表 表） 姓名 代丽 李霞 电话 028-85058465-8012 028-85058465-8012 办公地址 四川省成都市高新区科园南路 四川省成都市高新区科园南路 海创药业股份有限公司2025 年半年度报告摘要 电子信箱 ir@hinovapharma.com ir@hinovapharma.c ...

证券代码：688302 证券简称：海创药业 公告编号：2025-036 海创药业股份有限公司 本公司董事会及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 一、董事会会议召开情况 海创药业股份有限公司（以下简称"公司"）第二届董事会第十一次会议 于2025年8月13日在公司会议室以现场结合通讯表决方式召开，会议通知已于 事7名，会议由董事长YUANWEI CHEN（陈元伟）先生主持。本次会议的召集、召 开、议案审议程序符合《中华人民共和国公司法》等有关法律、行政法规、部 门规章、规范性文件和《公司章程》的有关规定，会议决议合法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 公司董事会认为：2025 年半年度报告的编制和审议程序符合相关法律法规 及《公司章程》等内部规章制度的规定；公司 2025 年半年度报告的内容与格式 符合相关规定，公允地反映了公司 2025 年半年度的经营成果、财务状况等事项； 报 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-037 海创药业股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 表决结果：同意3票，反对0票，弃权0票。 一、监事会会议召开情况 海创药业股份有限公司（以下简称"公司"）第二届监事会第十次会议于2025 年8月13日在公司会议室以现场方式召开，会议通知已于2025年8月8日以电子邮件等 形式送达全体监事。本次会议应到监事3名，实到监事3名，会议由监事会主席兰建 宏先生主持。本次会议的召集、召开、议案审议程序符合《中华人民共和国公司法》 等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定，会议 决议合法、有效。 二、监事会会议审议情况 全体监事对本次监事会会议议案进行了审议，经表决形成如下决议： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为：公司2025年半年度报告及其摘要的编制和审议程序符合相关法律 法规及《公司章程》等内部规章制度的规定；其内容与格式符合相关规定，公允地 反映了公司2025年半年 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-034 海创药业股份有限公司 关于取消监事会、修订《公司章程》及 制定、修订和废止部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 海创药业股份有限公司(以下简称"公司")于 2025 年 8 月 13 日召开第二届 董事会第十一次会议，审议通过了《关于取消公司监事会并修订 <公司章程> 的议 案》 《关于制定、修订和废止公司部分治理制度的议案》，同日召开第二届监事会 第十次会议审议通过了《关于取消公司监事会并修订 <公司章程> 的议案》，现将 具体情况公告如下: 一、取消监事会的相关情况 根据《中华人民共和国公司法》(以下简称"《公司法》")《关于新公司法 配套制度规则实施相关过渡期安排》《上市公司章程指引(2025 年修订)》(以下 简称"《章程指引》")等相关法律法规、规章及其他规范性文件的规定，结合公 司实际情况，公司拟不再设置监事会与监事，监事会部分的职权由董事会审计委 员会行使， 《海创药业股份有限公司监事会议事规则》相应废止 ...

Summary of Key Points Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has provided a detailed report on the management and usage of raised funds as of June 30, 2025, highlighting the total amount raised, its allocation, and the management protocols in place to ensure compliance and security of the funds [1][2]. Fundraising Overview - The company raised a total of RMB 1,062,699,200.00 through the issuance of 24,760,000 shares at RMB 42.92 per share, with a net amount of RMB 995,113,315.68 after deducting issuance costs [1][2]. - As of June 30, 2025, the cumulative usage of the raised funds amounted to RMB 871,447,067.89, leaving a balance of RMB 147,244,678.39, which includes RMB 23,578,430.60 from cash management [1][2]. Fund Management Practices - The company has established a fundraising management system to regulate the storage, management, and usage of the raised funds, ensuring compliance with relevant regulations [1][2]. - A tripartite supervision agreement has been signed with the underwriter and banks to clarify the rights and obligations of all parties involved in the management of the funds [1][2]. Actual Usage of Funds - The report indicates that there were no instances of using raised funds to replace pre-invested amounts or to temporarily supplement working capital during the reporting period [2][3]. - The company has approved the use of up to RMB 170 million of temporarily idle funds for cash management, investing in high-security and liquid financial products [2][3]. Project Delays and Adjustments - The company has postponed the completion date for certain fundraising projects, including the "R&D Production Base Construction Project" to December 31, 2025, and parts of the "Innovative Drug R&D Project" to December 31, 2026, due to implementation progress considerations [2][3]. - No changes have been made to the investment projects or their total amounts, ensuring that the adjustments do not adversely affect the company's operations or shareholder interests [3][4].